NEW YORK (GenomeWeb News) – Beckman Coulter today said that it has formed Beckman Coulter Genomics, which combines the operations of its Agencourt Bioscience business with Cogenics, a firm it recently purchased.
Orange County, Calif.-based Beckman said that the new company will offer researchers a "single genomic services resource with expanded global capabilities." It will offer a variety of services including sequencing, sample preparation, genotyping, gene expression, biological efficiency and safety testing, and support for regulatory compliance including CLIA.
The firm also noted that Beckman Coulter Genomics offers sequencing services on next-generation platforms including Roche 454's Genome Sequencer FLX with Titanium, Applied Biosystems' SOLiD, and Illumina's Genome Analyzer.
"Through the creation of Beckman Coulter Genomics, we have successfully brought together the industry's leading genomic service providers to offer our customers the highest-quality data and analysis," Richard Creager, Beckman Coulter group vice president of immunoassay, molecular diagnostics and genomic services, said in a statement.
Creation of the new business comes after Beckman Coulter's $17 million acquisition of Cogenics, a genomics services provider that was previously owned by Clinical Data.